Inflammatory networks underlying colorectal cancer

Lasry, Audrey; Zinger, Adar; Ben‐Neriah, Yinon

doi:10.1038/ni.3384

Cited by 426 publications

(352 citation statements)

References 164 publications

Supporting

Mentioning

339

Contrasting

Unclassified

Order By: Relevance

“…CRC has recently been understood to be tightly associated with chronic inflammation. CRC arises following chronic inflammation, such as in patients with inflammatory bowel diseases like ulcerative colitis or Crohn’s disease [1, 2]. …”

Section: Introductionmentioning

confidence: 99%

The Role of Tumor-Associated Macrophages in Colorectal Carcinoma Progression

Zhong¹,

Chen²,

Yang³

2018

Cell Physiol Biochem

103

View full text Add to dashboard Cite

Tumor-associated macrophages (TAMs) are one of the most abundant immune cells in the tumor microenvironment, and they play a pivotal role in prompting the various tumor growth. However, the role of TAMs in colorectal carcinoma (CRC) is controversial, because a few papers report that TAMs is beneficial to CRC patients. In this review, we discuss the good or bad roles of TAMs in CRC progression. Interestingly, recent studies provide strong evidence that TAMs facilitate CRC growth, but do not exert tumor suppressive activities. TAMs can stimulate CRC growth by altering extracellular matrix remodeling, tumor metabolism, angiogenesis, as well as the tumor microenvironment. Therefore, TAMs could serve as a target for CRC therapeutic treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of Tumor-Associated Macrophages in Colorectal Carcinoma Progression

Zhong¹,

Chen²,

Yang³

2018

Cell Physiol Biochem

103

View full text Add to dashboard Cite

show abstract

“…For example, persistent infection with Helicobacter pylori causes chronic atrophic gastritis which may lead to dysplasia and gastric carcinoma [100]. Moreover, there is a wellknown connection between colorectal cancer and inflammation; however, it is not yet known whether chronic inflammation exacerbates the progression to colorectal cancer or if colorectal cancer stimulates the secretion of cytokines that then stimulate a chronic inflammatory response [109]. The advent of high-throughput techniques for analyzing glycan structures as well as measuring levels of inflammatory glycoproteins based on both their protein and glycan content should elicit much research to address these questions in the near future.…”

Section: Glycoprotein Assays and Cancermentioning

confidence: 99%

Inflammatory glycoproteins in cardiometabolic disorders, autoimmune diseases and cancer

Connelly

Gruppen

Otvos

et al. 2016

Clinica Chimica Acta

View full text Add to dashboard Cite

The physiological function initially attributed to the oligosaccharide moieties or glycans on inflammatory glycoproteins was to improve protein stability. However, it is now clear that glycans play a prominent role in glycoprotein structure and function and in some cases contribute to disease states. In fact, glycan processing contributes to pathogenicity not only in autoimmune disorders but also in atherosclerotic cardiovascular disease, diabetes and malignancy. While most clinical laboratory tests measure circulating levels of inflammatory proteins, newly developed diagnostic and prognostic tests are harvesting the information that can be gleaned by measuring the amount or structure of the attached glycans, which may be unique to individuals as well as various diseases. As such, these newer glycan-based tests may provide future means for more personalized approaches to patient stratification and improved patient care. Here we will discuss recent progress in high-throughput laboratory methods for glycomics (i.e. the study of glycan structures) and glycoprotein quantification by methods such as mass spectrometry and nuclear magnetic resonance spectroscopy. We will also review the clinical utility of glycoprotein and glycan measurements in the prediction of common low-grade inflammatory disorders including cardiovascular disease, diabetes and cancer, as well as for monitoring autoimmune disease activity.

show abstract

“…Colorectal carcinogenesis involves a heterogeneous oncogenic process influenced by differing sets of genetic and epigenetic alterations, diet, microbiota, and host immunity (7–10). Potent lymphocytic reactions and higher density of T cells in colorectal carcinoma tissue have been associated with better patient survival, supporting a major role of antitumor immunity in inhibiting tumor progression (11–16).…”

Section: Introductionmentioning

confidence: 99%

Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer

Masugi

Nishihara

Hamada

et al. 2017

Cancer Immunology Research

View full text Add to dashboard Cite

Expression of the immune-checkpoint ligand CD274 (programmed cell death 1 ligand 1, PD-L1, from gene CD274) contributes to suppression of antitumor T cell–mediated immune response in various tumor types. However, the role of PDCD1LG2 (PD-L2, CD273, from gene PDCD1LG2) in the tumor microenvironment remains unclear. We hypothesized that tumor PDCD1LG2 expression might be inversely associated with lymphocytic reactions to colorectal cancer. We examined tumor PDCD1LG2 expression by immunohistochemistry in 823 colon and rectal carcinoma cases within two U.S.-nationwide cohort studies and categorized tumors into quartiles according to the percentage of PDCD1LG2–expressing carcinoma cells. We conducted multivariable ordinal logistic regression analysis to assess the associations of tumor PDCD1LG2 expression with Crohn’s-like lymphoid reaction, peritumoral lymphocytic reaction, intratumoral periglandular reaction, or tumor-infiltrating lymphocytes, controlling for potential confounders, including microsatellite instability, CpG island methylator phenotype, long-interspersed nucleotide element-1 methylation, and KRAS, BRAF, and PIK3CA mutations. Tumor PDCD1LG2 expression was inversely associated with Crohn’s-like lymphoid reaction (Ptrend = 0.0003). For a unit increase in the three-tiered ordinal categories of Crohn’s-like lymphoid reaction, a multivariable odds ratio in the highest (vs lowest) quartile of the percentage of PDCD1LG2–expressing tumor cells was 0.38 (95% confidence interval, 0.22–0.67). Tumor PDCD1LG2 expression was not associated with peritumoral lymphocytic reaction, intratumoral periglandular reaction, tumor-infiltrating lymphocytes, or patient survival (Ptrend>0.13). Thus, tumor PDCD1LG2 expression is inversely associated with Crohn’s-like lymphoid reaction to colorectal cancer, suggesting a possible role of PDCD1LG2–expressing tumor cells in inhibiting the development of tertiary lymphoid tissues during colorectal carcinogenesis.

show abstract

Inflammatory networks underlying colorectal cancer

Cited by 426 publications

References 164 publications

The Role of Tumor-Associated Macrophages in Colorectal Carcinoma Progression

The Role of Tumor-Associated Macrophages in Colorectal Carcinoma Progression

Inflammatory glycoproteins in cardiometabolic disorders, autoimmune diseases and cancer

Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer

Contact Info

Product

Resources

About